ANEW Medical - KLTO Forward P/S Multiple
Klotho Neurosciences Inc (KLTO) is currently implementing a long-term plan to develop innovative neurobiological treatments. The funding for preclinical trials of new drugs is based on attracted investments. The development of biologics based on the Klotho protein to combat dementia is supported by patents. The forward P/S ratio demonstrates market demand, with the parameter value equal to .
KLTO (anewmeds.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Klotho Neurosciences Inc|KLTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Klotho Neurosciences|KLTO - Company Total Debt Obligations|Debts to Book Capitalization KLTO|KLTO - Company Long-Term Liabilities|Company Short-Term Debts Klotho Neurosciences|Quick Ratio anewmeds.com
- net income and valuation multiples indicators:
KLTO - Company Net Income|Expected Profit Klotho Neurosciences Inc|KLTO - Price to Earnings Multiple|Forward P/E Multiple Klotho Neurosciences|KLTO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple KLTO|KLTO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Klotho Neurosciences|KLTO - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months anewmeds.com|KLTO - Earnings per share increase in current year|Earnings growth forecast for next year Klotho Neurosciences Inc
- total revenue and sales volume data:
Comprehensive company analysis:ANEW Medical, Inc. KLTO
Analyzing the forward price-to-sales ratio chart allows for an assessment of the market value of Klotho Neurosciences Inc (KLTO) through the lens of its scientific authority in neurodegeneration therapy. This indicator compares current market capitalization with expected sales, enabling investors to determine the business's margin of safety and identify hidden undervaluation or risks of declining demand for the company's innovative drugs.
Competitors of Klotho Neurosciences Inc (KLTO)
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|xenon-pharma.com (XENE) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|SUPN: Forward Price to Sales|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|Market Cap to Expected Sales Ratio biohavenpharma.com (BHVN)|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Trevi Therapeutics Inc (TRVI) - Forward Price-to-Revenue Multiple|PRAX: Forward P/S Multiple|AVXL - Market Cap to Expected Sales Ratio|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Prothena Corporation PRTA|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|Annexon Biosciences - Market Cap to Projected Revenue|Forward P/S Multiple OMER (Omeros)|NGNE - Forward Price-to-Revenue Multiple|AC Immune - Forward P/S Multiple|Market Cap to Future Revenue Ratio voyagertherapeutics.com|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|SCLX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple TVGN|ACOG: Forward Price to Sales|Forward P/S Multiple CGTX|Market Cap to Expected Sales Ratio inhibikase.com|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Vistagen Therapeutics (VTGN) - Forward Price-to-Revenue Multiple|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|acumenpharm.com (ABOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CervoMed|Price-to-Projected Revenue Ratio ATHE|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|Price to Expected Revenue Ratio PEPG|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|relmada.com (RLMD) - Market Cap to Future Revenue Ratio|ANVS - Price-to-Projected Revenue Ratio|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio NeuroSense Therapeutics Ltd. (NRSN)|Forward Price-to-Revenue Multiple RVPH|Forward P/S Multiple MetaVia, Inc.|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT (heliusmedical.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Future Revenue Ratio|NERV - Price-to-Projected Revenue Ratio|ATHA - Forward P/S Multiple|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|ALZN (Alzamend Neuro) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Future Revenue Ratio Protagenic PTIX|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|Price to Expected Revenue Ratio CRGT|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Chromocell|ELYM (eliemtx.com) - Forward Price-to-Revenue Multiple|Intra-Cellular Therapies, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Market Cap to Projected Revenue MRNS (Marinus Pharmaceuticals Inc)|Forward P/S Multiple NKGN|NRBO - Market Cap to Future Revenue Ratio|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple synaptogen.com SNPX|TRVN - Price-to-Projected Revenue Ratio|Forward Price to Sales VIGL (Vigil Neuroscience)|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
